Skip to main content

Table 5 GI symptoms and QOL comparisons between IBS-D patients with and without SIBO eradication after rifaximin treatment

From: Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome

Clinical factors LHBT (+) LHBT (−) P value
GI symptoms (mean) 7.88 ± 6.15 8.95 ± 5.23 0.531
Abdominal discomfort 1.64 ± 1.29 1.20 ± 1.20 0.243
Abdominal distension 0.92 ± 1.04 0.90 ± 1.29 0.956
Abdominal pain 1.64 ± 1.35 1.45 ± 1.28 0.631
Defecatory urgency 1.32 ± 1.44 2.05 ± 1.28 0.078
Diarrhea 1.20 ± 1.29 1.95 ± 1.10 0.051
Incomplete evacuation 1.16 ± 1.11 1.55 ± 1.15 0.256
Quality of life (mean) 579.93 ± 106.11 599.05 ± 88.29 0.513
Physical Functioning 96.20 ± 4.63 98.25 ± 3.73 0.107
Role-physical 70.00 ± 35.36 81.25 ± 25.49 0.222
Bodily pain 71.92 ± 14.29 73.68 ± 15.41 0.697
General Health 53.60 ± 19.72 53.85 ± 16.69 0.963
Vitality 63.80 ± 14.74 64.00 ± 15.01 0.965
Social Functioning 84.57 ± 12.92 82.95 ± 13.41 0.685
Role-Emotional 72.00 ± 32.89 81.67 ± 33.29 0.336
Mental Health 67.84 ± 17.42 63.40 ± 18.55 0.417
  1. Note: IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant IBS; GI symptoms, gastrointestinal symptoms; QOL, quality of life; SIBO, small intestinal bacterial overgrowth